mauro_gitto Profile Banner
Mauro Gitto Profile
Mauro Gitto

@mauro_gitto

Followers
215
Following
491
Media
3
Statuses
91

MD, Research Fellow at @IcahnMountSinai Cardiology Resident at @HumanitasMilano

Milano, Lombardia
Joined November 2013
Don't wanna be here? Send us removal request.
@GGStefanini
Giulio Stefanini
1 day
Are GLP-1 receptor agonists plaque modifiers? 🫀 In diabetic ACS patients, 1-year GLP-1RA therapy led to significant plaque regression and metabolic reprogramming. Preliminary evidence just published ⬇ 🔗 https://t.co/EPtjG38EB0 @mauro_gitto @HumanitasMilano
Tweet card summary image
link.springer.com
Acta Diabetologica - Despite advances in therapeutic strategies a significant proportion of acute coronary syndrome (ACS) patients experience early coronary artery disease (CAD) progression,...
0
1
4
@Sticchi_Alex
Alessandro Sticchi
9 months
0
10
28
@PCRonline
PCRonline 🫀
11 months
#EAPCI/PCR Journal Club: A randomised trial of sirolimus- versus paclitaxel-coated balloons for de novo coronary lesions @mauro_gitto & @NicolaRyanI1 review ✍️this study which compares a novel sirolimus-coated with a clinically proven paclitaxel-coated 🎈 demonstrating
4
11
25
@ACCinTouch
American College of Cardiology
1 year
The #ACCBOT has approved the College's newest officers and trustees who will assume their roles in March 2025 following #ACC25 in Chicago, IL. Congratulations @ChrisKramerMD, @Drroxmehran, @SamOJonesMD and @garosemd! 🎉 Read more: https://t.co/WwfqQFdpxz #ACCLeadership
14
23
76
@leoneppmd
Pier Pasquale Leone
2 years
Fantastic opportunity to present new #DCB 3.0 registry data from @HumanitasMilano Exciting sessions including: - Everolimus-eluting 🎈 - SCB vs. PCB - TRANSFORM I So much more coming! @Antocol17 @BernardCortese #BrunoScheller #PatrickSerruys #ManelSabatè
1
4
21
@mauro_gitto
Mauro Gitto
2 years
Thrilled to present the results of our study on #DCB based LAD PCI at #TCT2023 in San Francisco and to see the full paper simultaneously published on @CircIntv One more piece of evidence that supports the use of a #DCB based treatment for diffuse coronary artery disease.
@CircIntv
CircInterventions
2 years
1
3
19
@RCMjournal
Reviews in Cardiovascular Medicine
3 years
#RCM-Special Issue: Present and future of #tricuspid #regurgitation (1/5) 🚂Etiology, epidemiology, pathophysiology and management of tricuspid regurgitation: an overview @fracond_94 @mauro_gitto @GGStefanini #tricuspidregurgitation #TR Full Text https://t.co/uD8cC517Cq
0
1
5
@mauro_gitto
Mauro Gitto
3 years
In the study by @MintenLennert, CAD presence and ⬆️ SS in TAVR candidates were associated with ⬆️ all-cause and CV death at 5y. However, PCI and completeness of revasc had no impact of mortality. Have a look at our editorial 👉 https://t.co/AwDLBcv6oQ @GGStefanini @JACCJournals
1
6
19
@mauro_gitto
Mauro Gitto
4 years
Biochemical efficacy of #SGLT2 inhibitors by cardiovascular risk profile and volume status in a real-world diabetic population. Just accepted in @JCVPOnline. Take a look!
@JCVPOnline
Journal of Cardiovascular Pharmacology
4 years
0
0
1
@InvasiveCardiol
Journal of Invasive Cardiology
4 years
ICYMI
@YaleCardiology
Yale Cardiology
4 years
The integration of automated tools may provide a more accurate estimate of coronary stenosis in women with ischemic heart disease, research by @sealtin1 and @mauro_gitto in @InvasiveCardiol suggests. Learn about the WOMEN FiRST trial: https://t.co/ToLge97WdL @YaleMed @YaleIMed
0
3
9
@RoyTaoutel
Roy Taoutel, MD
4 years
Such a great honor to be part of this amazing trial! Check out our published work👇🏻 #WOMEN_FiRST @sealtin1 @mauro_gitto @YaleCardiology #CardioTwitter
@YaleCardiology
Yale Cardiology
4 years
The integration of automated tools may provide a more accurate estimate of coronary stenosis in women with ischemic heart disease, research by @sealtin1 and @mauro_gitto in @InvasiveCardiol suggests. Learn about the WOMEN FiRST trial: https://t.co/ToLge97WdL @YaleMed @YaleIMed
2
4
16
@SJcardio
Sasanka JayasuriyaMD
4 years
Congrats @sealtin1 @mauro_gitto @RoyTaoutel on an important and timely publication . Wire free assessment always preferred when one wire perf/dissection is seen in real time. @mirvatalasnag @BinitaShahMD @biljana_parapid @avolgman @JDawnAbbott1 @saraceciliamtz @sandylewis
@sealtin1
Elissa Altin
4 years
Congratulations to our team @mauro_gitto @RoyTaoutel and the YCRG core lab for using novel QFR in women with stable coronary syndromes. Novel wire free assessments of coronary hemodynamics are powerful.
1
1
5
@sealtin1
Elissa Altin
4 years
Congratulations to our team @mauro_gitto @RoyTaoutel and the YCRG core lab for using novel QFR in women with stable coronary syndromes. Novel wire free assessments of coronary hemodynamics are powerful.
@YaleCardiology
Yale Cardiology
4 years
The integration of automated tools may provide a more accurate estimate of coronary stenosis in women with ischemic heart disease, research by @sealtin1 and @mauro_gitto in @InvasiveCardiol suggests. Learn about the WOMEN FiRST trial: https://t.co/ToLge97WdL @YaleMed @YaleIMed
1
6
17
@mauro_gitto
Mauro Gitto
4 years
Comparison of #QCA, #QFR and visual assessment (VA) in #women with stable CAD: -> ⬆️ %DS at VA vs. QCA -> ⬆️ discrepancy observed in angiographically severe lesions -> 1/3 of severe lesions at angiography had QFR >0.8 Read the full manuscript at
@YaleCardiology
Yale Cardiology
4 years
The integration of automated tools may provide a more accurate estimate of coronary stenosis in women with ischemic heart disease, research by @sealtin1 and @mauro_gitto in @InvasiveCardiol suggests. Learn about the WOMEN FiRST trial: https://t.co/ToLge97WdL @YaleMed @YaleIMed
1
3
9
@italian_cot
Italian Cardiologists Of Tomorrow
4 years
0
4
9
@RCMjournal
Reviews in Cardiovascular Medicine
4 years
0
6
6